Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Takeda Slips to 3rd Place in 25 Major Pharmas’ Operating Profit Ranking
May 20, 2013
-
BUSINESS FY2012 Sales Up 18% for Both Generic-Only Makers, Research-Driven Pharmas’ Generic Units; Govt Incentive Measures Biggest Contributor
May 17, 2013
-
BUSINESS FY2012 Japan Pharma Market: Sales of Major Long-Listed Drugs Tumble 30-40%
May 16, 2013
-
REGULATORY CSIMC Approves Listing of 15 New APIs/19 Products Including Pfizer’s Xeljanz with Expected Peak Sales of 59.7 Billion Yen
May 16, 2013
-
BUSINESS Eight Companies Initiate Voluntary Recall of Enalapril Generics Due to Deviations from Specifications
May 15, 2013
-
BUSINESS Four Leading Wholesalers See Clear Recovery in Pharmaceutical Wholesale Business
May 14, 2013
-
REGULATORY PMDA-WEST to Be Launched in Osaka in October to Undertake Consultation Services, GMP Inspections
May 13, 2013
-
BUSINESS MTPC Royalties Reach 19.5 Billion Yen from Out-Licensed Gilenya
May 10, 2013
-
BUSINESS Takeda Sees Sales Rise on Expanding Europe, Emerging Market Biz in FY2012, Yet Operating Profit Sags 50%
May 10, 2013
-
BUSINESS No Prospects of Reaching Agreement on Delivery Prices with Wholesalers Even after the Fiscal Year End: Pres. Tajiri of Medical System Network
May 10, 2013
-
BUSINESS Takeda to Acquire US Dengue Vaccine Developer Inviragen
May 9, 2013
-
BUSINESS IFRS Implications to Be Seen in In-Licensed Products, M&A Processing
May 9, 2013
-
ORGANIZATION Kyokai Kenpo Launches Trial Notification Service on Copayment Differences between Original, Generic Anti-Allergy Drugs
May 8, 2013
-
ACADEMIA Nat’l University Hospitals Sharing Information of Drug Purchase Prices through Central Database
May 7, 2013
-
BUSINESS Boehringer to Enter Oncology Market, Hire 100 MRs in Japan
May 2, 2013
-
BUSINESS Novartis Investigating Employee Involvement in Retracted Diovan Papers
May 1, 2013
-
REGULATORY First Committee Recommends Approval for New Gout, Hyperuricemia Treatment, Antihypertensive Tape Formulation
May 1, 2013
-
REGULATORY PMRJ Introduces “RS Expert Certification System”
April 30, 2013
-
BUSINESS Boehringer Filed NDA for Afatinib in Japan: Chairman
April 26, 2013
-
BUSINESS Edoxaban Will Be Key to Achieving Targets in Daiichi Sankyo’s New 5-Year Business Plan
April 26, 2013
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…